DiaMedica Therapeutics Inc
$ 8.53
-1.16%
13 Feb - close price
- Market Cap 449,428,000 USD
- Current Price $ 8.53
- High / Low $ 9.04 / 8.47
- Stock P/E N/A
- Book Value 0.99
- EPS -0.74
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -0.64 %
- 52 Week High 10.42
- 52 Week Low 3.19
About
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$15.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-06 | 2025-03-17 | 2024-11-11 | 2024-08-07 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-28 |
| Reported EPS | -0.17 | -0.18 | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.16 | -0.2 | -0.14 |
| Estimated EPS | -0.17 | -0.19 | -0.18 | -0.1725 | -0.15 | -0.16 | -0.16 | -0.14 | -0.13 | -0.18 | -0.16 | -0.14 |
| Surprise | 0 | 0.01 | 0 | -0.0075 | 0 | 0.03 | 0.02 | 0 | 0.01 | 0.02 | -0.04 | 0 |
| Surprise Percentage | 0% | 5.2632% | 0% | -4.3478% | 0% | 18.75% | 12.5% | 0% | 7.6923% | 11.1111% | -25% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DMAC
2026-02-07 12:59:06
DiaMedica Therapeutics (NASDAQ:DMAC) has received a consensus "Moderate Buy" rating from six analysts, with an average one-year price target of $12.33. Shares opened at $8.14, and the company recently missed EPS estimates, reporting ($0.17) for the quarter. Insider activity shows a significant purchase by major shareholder Jan Stahlberg, who acquired 240,352 shares, increasing his stake to over 8.3 million shares.
2026-01-24 12:57:32
Insiders at DiaMedica Therapeutics Inc. (NASDAQ:DMAC) now own 47% of the company's shares. This significant ownership suggests a vested interest in the company's growth, especially following recent insider purchases and a 12% stock gain. The top five shareholders collectively hold 52% of the company, with individual insiders making up the largest group.
2026-01-24 04:28:33
Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating for Diamedica Therapeutics (DMAC) with a price target of $25.00, while the company's shares closed at $7.97. Despite a reported quarterly GAAP net loss of $8.62 million, corporate insider sentiment for DMAC stock is positive, marked by significant insider share purchases. The overall Street consensus for Diamedica Therapeutics is a Strong Buy with an average price target of $17.00.
2026-01-22 16:57:32
Cantor Fitzgerald has reiterated an Overweight rating and a $25.00 price target for DiaMedica Therapeutics Inc. (NASDAQ:DMAC), highlighting the potential of its DM199 treatment for pre-eclampsia. The firm's positive outlook is based on DM199's mechanism of restoring placental blood flow and its "remarkable early efficacy with a favorable safety profile." Despite recent earnings meeting expectations, the company is undertaking an additional non-clinical study for DM199 in a rabbit model as requested by the FDA, with results expected by Q2 2026.
2026-01-22 13:27:51
Cantor Fitzgerald has reaffirmed its Overweight rating and a $25.00 price target for DiaMedica Therapeutics Inc. (NASDAQ:DMAC), indicating a strong positive outlook on the company's DM199 treatment. The firm highlights DM199's mechanism in restoring placental blood flow and noted promising early efficacy in pre-eclampsia with a favorable safety profile. DiaMedica recently reported Q3 2025 earnings, increased cash reserves, and will conduct an additional non-clinical study for DM199 as requested by the FDA.
2026-01-18 17:27:51
DiaMedica Therapeutics (NASDAQ:DMAC) experienced a 22.8% reduction in short interest during December, totaling 4,093,770 shares, or 8.5% of its float. Major shareholder Jan Stahlberg increased his stake, and insiders have purchased over 1 million shares in the last three months. Analysts maintain a "Moderate Buy" consensus with a $12.33 price target, while the stock currently trades around $7.57.
